Medicair is a rapidly growing company, manufacturing and distributing generic medicines in a broad range of categories. It produces and distributes branded generics and medical devices in the pharmaceutical forms of solids, semi-solids, liquids and sprays for nasal, inhalation and derma use, as well as food supplements and cosmetics. The company specializes in providing manufacturing solutions for MDI inhalers, nasal sprays, pharmaceutical and medical device sprays, being one of only a selected few companies in Europe to offer this type of production forms and have this in-depth know-how.
Our vision is to become a global leading provider of innovative and high quality medicinal solutions, with integrity, consistency, efficiency and a passion to bring new ideas and technologies to the market.
Starting its commercial operations in 1998, Medicair introduced 2 branded generic products to the Greek market with great success and built up on that by creating a rich and diverse portfolio of over 80 product licenses. In 2012, the company acquired its own manufacturing facilities, which allowed to focus on distribution to the global market. Medicair currently distributes its products to more than 20 countries around the globe, the same time several products are under registration in multiple countries. In order to ensure the finest quality, Medicair’s state of the art manufacturing facilities comply with the highest manufacturing process standards of “Good Manufacturing Practices”, as defined by the European Union and the World Health Organisation.
Our mission is to develop effective medicinal products and technologies that contribute to the improvement of the quality of life for a wide range of patients, in an affordable way that makes no compromises on quality.
Medicair is committed to growth and innovation, thus investing more than 7% of its turnover on research that allows the company to remain competitive and constantly improve, renew and upgrade its portfolio with advanced, effective and safe quality products. Today, the company is one of the major pharmaceutical companies in Greece, owning not only a respectable market share, but also valuable expertise. With more than 10 innovative products launching until 2020, the company is well on its way to the top.